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Summary
Background The life expectancy of HIV-positive individuals receiving antiretroviral therapy (ART) is approaching that 
of HIV-negative people. However, little is known about how these populations compare in terms of health-related 
quality of life (HRQoL). We aimed to compare HRQoL between HIV-positive and HIV-negative people in Zambia and 
South Africa.
Methods As part of the HPTN 071 (PopART) study, data from adults aged 18–44 years were gathered between 
Nov 28, 2013, and March 31, 2015, in large cross-sectional surveys of random samples of the general population in 
21 communities in Zambia and South Africa. HRQoL data were collected with a standardised generic measure of 
health across five domains. We used β-distributed multivariable models to analyse differences in HRQoL scores 
between HIV-negative and HIV-positive individuals who were unaware of their status; aware, but not in HIV care; in 
HIV care, but who had not initiated ART; on ART for less than 5 years; and on ART for 5 years or more. We included 
controls for sociodemographic variables, herpes simplex virus type-2 status, and recreational drug use.
Findings We obtained data for 19 750 respondents in Zambia and 18 941 respondents in South Africa. Laboratory-
confirmed HIV status was available for 19 330 respondents in Zambia and 18 004 respondents in South Africa; 
4128 (21%) of these 19 330 respondents in Zambia and 4012 (22%) of 18 004 respondents in South Africa had 
laboratory-confirmed HIV. We obtained complete HRQoL information for 19 637 respondents in Zambia and 
18 429 respondents in South Africa. HRQoL scores did not differ significantly between individuals who had initiated 
ART more than 5 years previously and HIV-negative individuals, neither in Zambia (change in mean score –0·002, 
95% CI –0·01 to 0·001; p=0·219) nor in South Africa (0·000, –0·002 to 0·003; p=0·939). However, scores did differ 
between HIV-positive individuals who had initiated ART less than 5 years previously and HIV-negative individuals in 
Zambia (–0·006, 95% CI –0·008 to –0·003; p<0·0001). A large proportion of people with clinically confirmed HIV 
were unaware of being HIV-positive (1768 [43%] of 4128 people in Zambia and 2026 [50%] of 4012 people in South 
Africa) and reported good HRQoL, with no significant differences from that of HIV-negative people (change in mean 
HRQoL score –0·001, 95% CI –0·003 to 0·001, p=0·216; and 0·001, –0·001 to 0·001, p=0·997, respectively). In 
South Africa, HRQoL scores were lower in HIV-positive individuals who were aware of their status but not enrolled 
in HIV care (change in mean HRQoL –0·004, 95% CI –0·01 to –0·001; p=0·010) and those in HIV care but not on 
ART (–0·008, –0·01 to –0·004; p=0·001) than in HIV-negative people, but the magnitudes of difference were small.
Interpretation ART is successful in helping to reduce inequalities in HRQoL between HIV-positive and HIV-negative 
individuals in this general population sample. These findings highlight the importance of improving awareness of 
HIV status and expanding ART to prevent losses in HRQoL that occur with untreated HIV progression. The gains in 
HRQoL after individuals initiate ART could be substantial when scaled up to the population level.
Funding National Institute of Allergy and Infectious Diseases, National Institute on Drug Abuse, National Institute of 
Mental Health, President’s Emergency Plan for AIDS Relief, International Initiative for Impact Evaluation, the Bill & 
Melinda Gates Foundation. 
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Introduction
The 2015 UNAIDS Fast-Track targets are a call to action to 
protect the health of the roughly 19·8 million people 
globally with no access to antiretroviral therapy (ART). 
The targets stipulate that by 2020, 90% of people with 
HIV know their status, 90% of people who know their 
status are on ART, and 90% of people on ART have 
suppressed viral loads. However, to reach these ambitious 
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targets, UNAIDS estimates that domestic and 
international investment in HIV programmes in low-
income and middle-income countries (LMICs) will need 
to increase by about a third, from an estimated 
US$19·2 billion available in 2014, to $26·2 billion by 2020.1 
It is difficult for policy makers to justify the large 
investments needed to step up HIV interventions from 
current health budgets when faced with many other 
urgent public health priorities.
A potentially large immediate benefit of ART, which has 
received little attention in policy debates, is its success in 
restoring the health-related quality of life (HRQoL) of 
people living with HIV. Studies of clinical cohorts have 
shown that most individuals at advanced stages of disease 
have improved health outcomes when on ART.2,3 However, 
little evidence exists about the HRQoL of HIV-positive 
people at various stages of engagement in HIV care, when 
benchmarked against the attainable HRQoL of the HIV-
negative population. Evidence about the effectiveness of 
ART in reducing the extreme inequalities in population 
health caused by HIV in high-burden settings is a crucial 
piece of evidence missing from the current debate. Such 
evidence would garner support for reducing the funding 
gap required to achieve the UNAIDS 2020 Fast-Track 
90-90-90 targets.
We did this study to compare the HRQoL of people 
living with HIV with that of individuals not infected with 
HIV.
Methods
Study population and data
We analysed data from a large cross-sectional random 
sample survey of the general population that was done in 
Zambia and South Africa as part of the HPTN 071 
(PopART) study.4 That study was an ongoing cluster-
randomised trial measuring the effect of a combination 
prevention intervention on HIV incidence at population 
level, measured in a population cohort of randomly 
sampled adults who are being followed up for 36 months. 
Full details of the study have been published elsewhere.4 
The trial has been implemented in 21 study communities: 
nine in the Cape Metro District and Cape Winelands 
Research in context
Evidence before this study
We searched MEDLINE, PubMed, and Embase on Feb 9, 2016, 
for studies published between Jan 1, 1995, and Dec 31, 2015, 
published in English, that compared the health-related quality 
of life (HRQoL) of people living with HIV with that of the 
general population across all World Bank income groups. 
We used the search terms “HIV”, “AIDS”, “quality-of-life”, and 
“population”. We excluded studies that focused exclusively on 
the health of HIV-positive individuals without comparison 
with the health of HIV-negative individuals or the general 
population, and studies that evaluated a specific health aspect 
(eg, depression) and not quality of life across all dimensions, 
that focused on specific populations (eg, pregnant mothers, 
diamond miners), or patients with adverse events, particular 
comorbidities, or co-infections. We identified five studies: 
three from high-income countries and two from South Africa. 
One study was published in 2014, and the others were at least 
12 years old (one was from 2004, two from 2000, and 
one from 1996). HIV-positive patient populations differed 
between studies; two studies comprised 2864 and 
3258 patients at all stages of disease, two studies focused on 
72 and 134 patients at earlier disease stages (exclusion 
criterion CD4 cell count <200 per µL or acute or terminal 
illness), and one study focused on 123 patients with advanced 
disease (exclusion criterion CD4 cell count >200 per µL). All 
studies found that HRQoL was lower in HIV-positive individuals 
than in the general population. The two studies from South 
Africa found that HRQoL was compromised across all 
dimensions. The three studies from high-income countries 
found that HRQoL was most affected by emotional 
functioning. One study found that physical functioning was 
worse for patients with AIDS, but not for patients with 
asymptomatic disease. Almost all previous studies evaluated 
HRQoL in HIV patients who attended a clinic, participated in a 
clinical study, or were receiving health care. Because these 
individuals sought care, their health could have been 
compromised and they were therefore not representative of 
the general HIV-positive population.
Added value of this study
This study is one of the most extensive and robust analyses of 
differences in HRQoL among HIV-positive and HIV-negative 
individuals in a random sample of the general population in 
sub-Saharan Africa since the rapid scale up of antiretroviral 
therapy (ART). HIV status was determined from blood samples 
taken during the survey and confirmed with laboratory testing. 
We did a direct comparison of HRQoL between HIV-positive 
people and HIV-negative people. Furthermore, our study design 
enabled adjustment for confounders that were collected for 
both groups in the same way. The data are a random sample of 
the general population, thus giving an estimate of the HRQoL 
of all people living with HIV, not just the most ill. The study 
provides a rare insight into the HRQoL of HIV-positive 
individuals at different stages of engagement with HIV care, 
even those who were not aware of their status or who were 
aware but not in HIV care.
Implications of all the available evidence
Our results can be used to estimate how many quality-adjusted 
life-years could be gained with HIV treatment because of 
reductions in morbidity. This is crucial information for policy 
makers to comprehensively assess the societal worth of HIV 
interventions aimed at increasing the number of individuals 
receiving treatment.
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District of the Western Cape Province of South Africa and 
12 in Zambia, spread across four provinces and six districts 
(appendix p 2).
The data used in this paper were taken from the baseline 
survey of the population cohort done between Nov 28, 2013, 
and March 31, 2015, and the laboratory-confirmed HIV 
status of all participants. In each of the 21 trial communities, 
a random sample of households was selected and visited 
by field staff who enumerated all adults aged 18–44 years. 
From this list, one adult from each household was 
randomly selected and provided informed consent to 
participate in the population cohort. Next, the entire 
population cohort survey was administered in the 
respondent’s preferred language by trained field workers. 
The HRQoL questions were embedded as a section in the 
population cohort survey. From each respondent, detailed 
information was gathered about HIV testing, self-reported 
HIV status, sociodemographics, health, and economic and 
behavioural aspects. Respondents self-reported their HIV 
status. If they self-reported being HIV-positive, they were 
asked whether they were in HIV care, and whether and for 
how long they had been on ART. After completion of the 
survey, a research nurse offered all respondents an on-the-
spot HIV rapid test with pretest and post-test counselling. 
HIV status was confirmed by testing of blood samples 
drawn from consenting participants (appendix p 3).
HRQoL information was gathered in South Africa with 
the certified translation of the EuroQol five dimensions, 
five levels questionnaire (EQ-5D-5L).5 Since no certified 
translation of the EQ-5D-5L was available for Zambia, the 
study team translated the questionnaire into regional 
Zambian dialects. The EQ-5D-5L measures HRQoL in 
five separate domains (mobility, self-care, ability to do 
daily activities, pain, and anxiety or depression) and each 
domain is measured with five levels (no problems, slight, 
moderate, severe, or unable to; appendix pp 3–4). Because 
the questions are not disease specific, the measured 
HRQoL of HIV-positive and HIV-negative people can be 
directly compared—an important feature for this study. 
EQ-5D has been used previously to study HRQoL in the 
general population and in people living with HIV in 
LMICs and high-income countries,6,7,8 and it is an 
appropriate generic tool for measuring HRQoL in patients 
with HIV/AIDS.9
A full ethics review of the trial protocol was done by 
the ethics committees of the University of Zambia, 
Stellenbosch University, the London School of Hygiene & 
Tropical Medicine, Imperial College London, and the US 
Centers for Disease Control and Prevention.
Statistical analysis
We used multivariate β regression models to evaluate 
the effect of HIV status and ART on HRQoL scores. We 
selected complementary log–log link functions over 
logit, probit, and log–log alternatives on the basis of the 
model that minimised Bayesian information criterion.10 
Two defining properties of the HRQoL utility score 
guided selection of the regression model. First, it has 
truncated support (ranging between 0 and 1). Second, as 
in the case of other studies,7 it was negatively skewed 
with a spike at the upper end of the scale. Such models 
have been widely applied in analysing variables that are 
constrained between 0 and 1 and are either positively or 
negatively skewed.11–13
β regressions are more robust than other commonly 
used approaches in estimating covariate effects on 
HRQoL.14 We used the betareg routine in Stata (version 14). 
Results are presented as marginal effects, whereby a 
negative effect represents the magnitude of reduction in 
the score. With HIV-negative individuals as the base case, 
the model included people with HIV in five categories: 
HIV positive and unaware of status (those reporting 
being negative or unaware of their status, but confirmed 
Zambia 
(n=19 750)
South Africa 
(n=18 941)
Age (years) 27 (7·2) 29 (7·4)
HRQoL score 0·88 (0·1) 0·89 (0·03)
Sex
Male 5428/19 733 (28%) 5816/18 612 (31%)
Female 14305/19 733 (73%) 12796/18 612 (69%)
Ethnic group
1 5827/19 750 (30%); Bemba 12 048/18 941 (64%); Xhosa
2 2453/19 750 (12%); Tonga 4803/18 941 (25%); multiracial
3 1547/19 750 (8%); Lozi 526/18 941 (3%); Afrikaner
4 1404/19 750 (7%); Chewa 1564/18 941 (8%); other
5 8519/19 750 (43%); other* ··
Christian 19 479/19 680 (99%) 15 140/18 270 (83%)
Educational level
School education less than 
grade 8 (primary school)
5544/19 668 (28%) 1472/18 466 (8%)
School education between 
grades 8 and 12 
(secondary school)
12 808/19 668 (65%) 15 947/18 466 (86%)
College, university, or other 
higher education
1316/19 668 (7%) 1047/18 466 (6%)
HSV-2-positive 8117/19 234 (42%) 8870/17 857 (50%)
Use recreational drugs 480/19 629 (2%) 689/18 432 (4%)
Alcohol consumption† 970/19 732 (5%) 1145/18 770 (6%)
HIV-negative 15 202/19 330 (79%) 13 992/18 004 (79%)
HIV-positive‡ 4128/19 330 (21%) 4012/18 004 (22%)
HIV-positive, unaware of status 1768/4128 (43%) 2026/4012 (50%)
HIV-positive, aware of status, 
not in HIV care§
487/4128 (12%) 350/4012 (9%)
HIV-positive, in HIV care, not yet 
on antiretroviral therapy§
177/4128 (4%) 173/4012 (4%)
HIV-positive, on antiretroviral 
therapy§
1585/4128 (38%) 1236/4012 (31%)
Status unknown 111/4128 (3%) 227/4012 (6%)
Data are mean (SD), n (%), or n/N (%). HRQoL=health-related quality of life. HSV-2=herpes simplex virus type 2. 
*All other ethnic groups varied between 0·03% and 6·69%. †Participant drinks five or more drinks of alcohol two or 
more times a week. ‡Numbers based on laboratory confirmed test results. §Numbers based on responses by those 
self-reporting being HIV-positive in the survey.
Table 1: Sample demographics
See Online for appendix
For the protocol see 
https://www.hptn.org/sites/
default/files/2016-05/HPTN%20
Protocol%20071%20V.3.0-%20
16%20Nov%202015%20
Final%20%281%29.compressed.
pdf
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as positive from the laboratory tests); HIV positive and 
aware of status, but not in HIV care; HIV positive and in 
HIV care, but not yet on ART; HIV positive and on ART 
initiated within the last 5 years; and HIV-positive people 
who initiated ART 5 or more years previously. The model 
included the adjustment variables age, sex, education, 
religion, ethnic group, herpes simplex virus type 2 status, 
and use of recreational drugs. We also included trial 
cluster dummy variables to capture community-level 
unobservable differences. We ran models separately for 
Zambia and South Africa. The appendix provides results 
for alternative specifications.
We analysed the five domains of HRQoL to determine 
which domains contributed to the observed effects on 
HRQoL. We used seemingly unrelated ordered probit 
regressions to take into account that an individual’s 
responses in each of the five domains might be correlated. 
For example, individuals reporting problems with 
mobility might also be more likely to report problems 
completing daily activities. This approach is a 
generalisation of the standard ordered probit regression 
model allowing for the error terms of each individual’s 
responses in the five domains to be correlated. In this 
case, we had five ordered probit equations (one for each 
domain) with error terms correlated across the 
five models. Negative marginal effects show the reduction 
in the probability of reporting no problems in the specific 
domain of health. We did the analysis with the cmp 
routine in Stata (version 14).
We used the results of the HRQoL score regressions to 
quantify the average quality-adjusted life-years (QALYs) 
that might be gained from treatment. For example, 
assuming each untreated HIV-positive individual has 
10 remaining years of life, irrespective of current age or 
disease stage, and those on ART have remaining years of 
life according to life tables by country, age, and sex, we 
Zambia South Africa
HIV-negative 
(n=15 145)*
HIV-positive 
(n=4102)*
p value for 
difference†
HIV-negative 
(n=13 648)*
HIV-positive 
(n=3898)*
p value for 
difference†
Mobility ·· ·· p<0·0001 ·· ·· p=0·25
No problems walking around 14 727 (97%) 3905 (95%) ·· 13 435 (98%) 3847 (99%) ··
Slight or moderate problems 
walking around
389 (3%) 169 (4%) ·· 199 (2%) 48 (1%) ··
Severe problems or unable 
to walk around
29 (<1%) 28 (<1%) ·· 14 (<1%) 3 (<1%) ··
Self-care ·· ·· p<0·0001 ·· ·· p=0·18
No problems washing 
and dressing myself
14 810 (98%) 3932 (96%) ·· 13 407 (98%) 3842 (99%) ··
Slight or moderate problems 
washing and dressing myself
320 (2%) 156 (4%) ·· 235 (2%) 53 (1%) ··
Severe problems or unable 
to wash or dress myself
15 (<1%) 14 (<1%) ·· 6 (<1%) 3 (<1%) ··
Daily activities ·· ·· p<0·0001 ·· ·· p=0·38
No problems doing my usual 
activities
14 608 (97%) 3860 (94%) 13 337 (98%) 3801 (98%) ··
Slight or moderate problems 
doing my usual activities
516 (3%) 226 (6%) ·· 301 (2%) 91 (2%) ··
Severe problems or unable to 
do my usual activities
21 (<1%) 16 (<1%) ·· 10 (<1%) 6 (<1%) ··
Pain ·· ·· p<0·0001 ·· ·· p=0·12
No pain or discomfort 13 201 (87%) 3425 (83%) ·· 13 068 (96%) 3710 (95%) ··
Slight or moderate pain 
or discomfort
1850 (12%) 640 (16%) ·· 568 (4%) 181 (5%) ··
Severe or extreme pain 
or discomfort
94 (<1%) 37 (1%) ·· 12 (<1%) 7 (<1%) ··
Anxiety or depression ·· ·· p<0·0001 ·· ·· p=0·02
Not anxious or depressed 13 873 (92%) 3642 (89%) ·· 13 069 (96%) 3699 (95%) ··
Slightly or moderately 
anxious or depressed
1186 (8%) 424 (10%) ·· 540 (4%) 188 (5%) ··
Anxious or depressed 86 (<1%) 36 (1%) ·· 39 (<1%) 11 (<1%) ··
HRQoL score 0·88 (0·04) 0·88 (0·06) 0·89 (0·3) 0·89 (0·4)
Data are n (%), n/N (%), or mean (SD), unless otherwise stated. HRQoL=health-related quality of life. *Numbers based on complete responses to the five dimensions of 
HRQoL and laboratory-confirmed HIV status.†p value (Wilcoxon rank-sum test) for the difference between HIV-negative and HIV-positive groups.
Table 2: Five health domain classifications for Zambia and South Africa
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can combine the remaining years of life with the predicted 
HRQoL scores for each country to generate the value of 
remaining years of life, taking into account the extension 
of life and HRQoL.
Role of the funding source
The funders of the study had no role in the study design, 
data collection, data analysis, data interpretation, or 
writing of the report. RT and KH had full access to the 
data in the study. RT had final responsibility for the 
decision to submit for publication.
Results
The full sample included responses from 19 750 (83%) of 
23 676 randomly selected individuals in Zambia and 
18 941 (88%) of 21 568 randomly selected individuals in 
South Africa. HIV status from laboratory-tested blood 
samples was available for 19 330 (98%) participants in 
Zambia and 18 004 (95%) participants in South Africa. 
4128 (21%) of these 19 330 respondents in Zambia and 
4012 (22%) of 18 004 respondents in South Africa had 
laboratory-confirmed HIV. 19 637 (99%) participants in 
Zambia and 18 429 (97%) participants in South Africa had 
complete EQ-5D-5L information.
Prevalence of HIV in the trial communities was similar 
in both countries (table 1). A large proportion of HIV-
positive participants were unaware of their status (table 1). 
Of HIV-positive participants aware of their HIV status, 
more reported being on ART in Zambia than in South 
Africa (table 1). Both countries had lower proportions of 
male respondents than female respondents (table 1). The 
unadjusted results show that HIV-positive people in 
Zambia reported lower levels of HRQoL than HIV-
negative people, particularly in the domain of pain, 
which had a 4 percentage-point difference between the 
two groups (table 2). Except for a significant difference in 
the domain of anxiety or depression, there was no 
difference in HRQoL between HIV-positive and HIV-
negative individuals in South Africa. Mean HRQoL score 
in HIV-positive and HIV-negative people was 0·88 in 
Zambia and 0·89 in South Africa (table 2).
Regression results show that, in Zambia, individuals 
who initiated ART less than 5 years previously reported 
significantly lower HRQoL scores than HIV-negative 
individuals (table 3). However, the difference is small and 
unlikely to be clinically meaningful. We recorded no 
additional differences in HRQoL between HIV-negative 
and HIV-positive individuals (table 3). Results for South 
Africa show that HRQoL did not differ between HIV-
positive individuals on ART and HIV-negative individuals 
(table 3). Compared with HIV-negative individuals, small 
reductions in HRQoL were reported by HIV-positive 
individuals who were aware of their status but not 
enrolled in HIV care and those in HIV-care but not yet on 
ART (table 3). Although significant, these magnitudes are 
again unlikely to represent meaningful reductions 
(table 3).
When we analysed the five domains of HRQoL, results 
for Zambia showed that HIV-positive individuals who 
had initiated ART less than 5 years previously were less 
likely than HIV-negative individuals to report no 
problems across all five domains (table 4). In both 
Zambia 
(18 910 observations)
South Africa 
(16 805 observations)
HIV-negative (base) 1 (ref) 1 (ref)
HIV-positive, unaware of status –0·001 
(–0·003 to 0·001); p=0·216
0·001 
(–0·001 to 0·001); p=0·997
HIV-positive, aware of status, not in care –0·002 
(–0·01 to 0·001); p=0·223
–0·004 
(–0·01 to –0·001); p=0·010
HIV-positive, in care, never taken ART 0·001 
(–0·01 to 0·07); p=0·695
–0·008 
(–0·01 to –0·004); p=0·0001
HIV-positive, initiated ART less than 5 years 
ago
–0·006 
(–0·008 to –0·003); 
p<0·0001
–0·001 
(–0·003 to 0·000); p=0·140
HIV-positive, initiated ART 5 years or more 
ago
–0·002 
(–0·01 to 0·001); p=0·219
0·000 
(–0·002 to 0·003); p=0·939
Age 18–25 years (base) 1 (ref) 1 (ref)
Age 25–34 years –0·003 
(–0·004 to –0·001); 
p<0·0001
0·00 
(0·001 to 0·001); p=0·513
Age >35 years –0·01 
(–0·009 to –0·006); 
p<0·0001 
–0·002 
(–0·003 to –0·001); p=0·0002
Women (base) 1 (ref) 1 (ref)
Men 0·001 
(0·000 to 0·002); p=0·151
0·001 
(0·001 to 0·002); p=0·001
Bemba (base Zambia), Xhosa (base South 
Africa)
1 (ref) 1 (ref)
Tonga (Zambia), multiracial (South Africa) 0 
(–0·002 to 0·002); p=0·827
0 
(–0·001 to 0·001); p=0·0991
Lozi (Zambia), Afrikaner (South Africa) 0·002 
(–0·001 to 0·004); p=0·149
–0·001 
(–0·004 to 0·002); p=0·0446
Chewa (Zambia) 0 
(–0·002 to 0·002); p=0·901
··
Other –0·001 
(–0·002 to 0·001); p=0·370
0 
(–0·001 to 0·002); p=0·0618
Other religion (base) 1 (ref) 1 (ref)
Christian 0·001 
(–0·004 to 0·006); p=0·727
0·001 
(0·000 to 0·002); p=0·037
School education less than grade 8 
(primary school, base)
·· ··
School education between grade 8 and 12 
(secondary school)
0·002 
(0·000 to 0·003); p=0·013
0·003 
(0·002 to 0·01); p<0·0001
College, university, or other higher education 0·002 
(–0·001 to 0·004); p=0·112
0·004 
(0·002 to 0·006); p=0·0007
HSV-2-negative (base) 1 (ref) 1 (ref)
HSV-2-positive –0·001 
(–0·002 to 0·000); p=0·088
0·001 
(–0·000 to 0·002); p=0·102
Does not use recreational drugs (base) 1 (ref) 1 (ref)
Uses recreational drugs –0·01 
(–0·01 to –0·002); 
p=0·0009
–0·002 
(–0·004 to 0·000); p=0·067
Community fixed effects Yes Yes
Data are change in mean health-related quality of life score (95% CI), unless otherwise stated. For all factor variables, 
each category is compared with the base category. ART=antiretroviral treatment. HSV-2=herpes simplex virus type 2.
Table 3: Multivariable analysis of factors associated with health-related quality of life
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countries, HIV-positive individuals on ART for at least 
5 years had a similar HRQoL to HIV-negative individuals 
across all five domains (table 4). In South Africa, 
individuals in HIV care who had never taken ART were 
less likely than HIV-negative individuals to report no 
problems with mobility, self-care, and daily activities 
(table 4). In both countries, individuals aware of their 
HIV-positive status but not in HIV care were significantly 
less likely to report no anxiety or depression than were 
HIV-negative individuals (table 4).
We estimate that, on average, each HIV-positive 
individual on ART would gain 26·24 QALYs in 
South Africa and 26·20 QALYs in Zambia, compared 
with an untreated individual. If we project these data to 
the UNAIDS 2016 estimates of 3·64 million individuals 
not yet on ART in South Africa, treating 90% of these 
individuals would equate to a gain of roughly 86 million 
QALYs as a direct benefit. Similar estimates for Zambia 
would mean 10·4 million QALYs could be gained 
from reaching 90% of the 0·44 million HIV-positive 
individuals not yet on ART.
Discussion
To our knowledge, this is the first and largest study to 
evaluate the differences in HRQoL between HIV-positive 
and HIV-negative individuals since the expansion of 
ART in LMICs with high HIV burden. Unlike most 
previous studies, which compared the HRQoL of HIV 
patients at clinics (who are often at advanced disease 
stages) with the HRQoL of the general population, this 
study is the first to evaluate HRQoL by awareness of 
infection and ART status in a random sample from the 
general population, using laboratory-confirmed HIV 
status. We estimated several multivariable models with 
different categorisations of HIV status. We did analyses 
separately for Zambia and South Africa. Although a 
multicountry analysis provides valuable added insight, 
the two countries have very different population and 
health-system characteristics; therefore, we refrained 
from a direct comparison of results between countries.
38% of HIV-positive individuals in Zambia and 31% in 
South Africa were receiving ART, and receipt of 
treatment raised their HRQoL to that of HIV-negative 
individuals. The only exception was individuals in 
Zambia who had initiated ART less than 5 years 
previously, who reported a lower HRQoL score than 
HIV-negative individuals; however, the difference was 
very small. Roughly 4% of HIV-positive people in both 
countries were in care and had not started ART. In 
South Africa, these individuals had lower HRQoL than 
HIV-negative individuals. This finding was due to the 
dimensions of mobility, self-care, and problems in doing 
daily activities, but differences in scores were small 
when compared with HIV-negative people. 12% of HIV-
positive people in Zambia and 9% of those in South Africa 
were aware of their status but not linked to care. In both 
countries, these individuals were more likely to report 
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being anxious or depressed than people without HIV. A 
high proportion of HIV-positive individuals were 
unaware of their status (43% in Zambia, 50% in 
South Africa). In both countries, these individuals 
reported the same HRQoL as HIV-negative individuals, 
possibly representing the asymptomatic nature of HIV 
infection in its earlier stages.
Modelling estimates for KwaZulu-Natal suggest that it 
would take an average of 4·9 years for 50% of HIV 
seroconverters to be linked to care.15 Our findings 
support the observation that, at any one time, most HIV-
positive people do not receive care and are not even 
aware of their status, but report good health. Overall, our 
estimates of differences are small and possibly not 
clinically relevant at the individual level. However, when 
scaled up to population level, they constitute a substantial 
loss in QALYs. Our calculations suggest that nearly 
100 million QALYs could be gained across the two 
countries if 90% of currently untreated individuals are 
on ART, but most of these gains are due to extension in 
length of life. Other research has shown that early 
mortality rates among adults accessing ART are high in 
the first year of ART in sub-Saharan Africa,16 and that 
many people enter care at an advanced stage of disease 
and with clinically significant comorbidities.17 Our 
findings call for strategies to avoid losses in HRQoL that 
occur before individuals receive ART, by aiming at early 
diagnosis, timely initiation of ART, and improvement of 
adherence. Delays in health-systems initiation of ART 
must be minimised, especially in patients who present 
with advanced immunodeficiency.
Previous studies from high-income countries6,18–20 and 
LMICs21,22 found that average HRQoL of HIV-positive 
individuals was overall lower than that of HIV-negative 
individuals. However, evidence is contradictory as to 
whether HIV-positive individuals with asymptomatic 
disease or viral suppression have the same20 or lower6 
HRQoL than HIV-negative people. We found smaller 
magnitudes of differences in HRQoL, by contrast with 
previous studies that compared clinical cohorts with the 
general population. In our sample from the general 
population, almost 60% of HIV-positive people belonged 
to one of two groups—either unaware of their status and 
potentially still in good health, or stable on ART for over 
5 years and therefore also in relatively good health. 
Therefore, comparison of our findings with previous 
studies is problematic. Additionally, all but one of these 
studies was done before access to testing and treatment 
was accelerated. Most previous studies also sampled 
patients enrolled in HIV care, who were likely to be at a 
more advanced stage of disease and not representative of 
the overall population of people living with HIV.18,20–22
The main strengths of this study are that data were 
gathered recently, covered a large sample of the general 
population, comprised both HIV-negative and HIV-
positive people from two countries, and enabled 
adjustment for several confounders that were collected 
for both groups in the same way. This approach allowed 
us to provide a rare insight into the HRQoL of HIV-
positive individuals at different stages of engagement 
with HIV care, including those who were not aware of 
their status or who were aware but not in HIV care. As 
the largest survey of HRQoL in these countries, our 
survey findings provide an important resource of quality-
of-life estimates for future studies.
Our study has limitations. Blood samples from 
respondents were tested for their HIV status, but no 
information about disease stage was available. Therefore, 
we could not differentiate HRQoL by confirmed disease 
stage. However, evidence shows that in sub-Saharan 
Africa, mean CD4 cell count at ART initiation has 
remained at about 152 per µL in the past decade.17 The 
group of individuals on ART in our study is thus likely to 
have been in more advanced clinical stages of HIV at 
treatment initiation, with associated lower HRQoL. Our 
results suggest that, with ART, average HRQoL scores 
recover to levels in the general population, a finding 
corroborated by clinical studies.3 We relied on self-reports 
of ART initiation, which might have been affected by 
recall bias. Men were under-represented in the sample 
because the survey was done during the day and fewer 
men were available at home for interviews. This 
imbalance might have biased results if there were 
systematic differences in reported HRQoL between sexes. 
Results from previous studies have suggested that women 
might report lower HRQoL than men at similar disease 
stages, but these studies used a different instrument.23,24 
Although we adjusted for a large number of possible 
confounders, some could have been unobserved and 
could have affected results if they differed systematically 
by HIV status. We had to use the health state valuations 
for Zimbabwe because valuations were not available for 
South Africa or Zambia. Stigma has been shown to 
substantially affect mental health of HIV-positive 
individuals,25 but this influence could be captured by the 
anxiety or depression dimension of the EQ-5D-5L.
The unique design of our study allowed us to identify 
the success of ART in reducing inequalities between the 
HRQoL of HIV-infected individuals and the HIV-negative 
population. But our findings are also a call to step up 
efforts to extend these benefits to the millions of people 
not yet on ART. Improved access to ART is considered the 
main reason for the marked increase in overall life 
expectancy in sub-Saharan Africa over the last decade.26–28 
Additionally, ART can reduce rates of sexual transmission 
of HIV,29 and substantial reductions in incidence, with 
associated savings in future treatment costs, have been 
predicted.30–35 However, the beneficial effect of ART on the 
HRQoL of HIV-positive individuals is often not the focus 
of attention. This noteworthy and direct benefit of 
treatment could provide important additional support to 
international advocacy efforts for the UNAIDS Fast-Track 
targets. Policy makers should remember the purpose of 
medical treatment is to add years to life, and life to years.
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